1 Gottschlich S, "Wegener’s granulomatosis in the head and neck region" 52 (52): 935-945, 2004
2 De Groot K, "Standardized neurologic evaluation of 128 patients with Wegener granulomatosis" 58 : 1215-1221, 2001
3 Khosroshahi A, "Rituximab for the treatment of IgG4-related disease : lessons from 10 consecutive patients" 91 : 57-, 2012
4 Ebbo M, "Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients" 12 (12): e0183844-, 2017
5 Wallace ZS, "IgG4-Related Disease : Clinical and Laboratory Features in One Hundred Twenty-Five Patients" 67 (67): 2466-2475, 2015
6 Falk RJ, "Granulomatosis with polyangiitis (Wegener’s):an alternative name for Wegener’s granulomatosis" 22 (22): 587-588, 2011
7 Yates M, "EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis" 75 : 1583-, 2016
8 Umehara H, "Comprehensive diagnostic criteria for IgG4-related disease, 2011" 22 : 21-30, 2012
9 Danlos FX, "Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease : a new overlap symdrome" 16 (16): 1036-1043, 2017
10 Umehara H, "A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details" 22 : 1-14, 2012
1 Gottschlich S, "Wegener’s granulomatosis in the head and neck region" 52 (52): 935-945, 2004
2 De Groot K, "Standardized neurologic evaluation of 128 patients with Wegener granulomatosis" 58 : 1215-1221, 2001
3 Khosroshahi A, "Rituximab for the treatment of IgG4-related disease : lessons from 10 consecutive patients" 91 : 57-, 2012
4 Ebbo M, "Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients" 12 (12): e0183844-, 2017
5 Wallace ZS, "IgG4-Related Disease : Clinical and Laboratory Features in One Hundred Twenty-Five Patients" 67 (67): 2466-2475, 2015
6 Falk RJ, "Granulomatosis with polyangiitis (Wegener’s):an alternative name for Wegener’s granulomatosis" 22 (22): 587-588, 2011
7 Yates M, "EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis" 75 : 1583-, 2016
8 Umehara H, "Comprehensive diagnostic criteria for IgG4-related disease, 2011" 22 : 21-30, 2012
9 Danlos FX, "Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease : a new overlap symdrome" 16 (16): 1036-1043, 2017
10 Umehara H, "A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details" 22 : 1-14, 2012